RELX Opens Bioscience Lab to Enhance Global E-Cigarette Research
17.9.2020 13:30:00 EEST | Business Wire | Press release
RELX Technology today announced the company has started operations at its newly-established e-cigarette bioscience laboratory to conduct systematic research on the effects of e-cigarettes through in vivo and in vitro tests, as well as conduct pre-clinical safety assessments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005346/en/
RELX Technology announced the company has started operations at its newly-established e-cigarette bioscience laboratory (Photo: Business Wire)
The bioscience laboratory, located in International Bioindustry Valley, Shenzhen is currently conducting research on the impact of RELX products on animal cardiovascular, respiratory, and nervous systems, in order to better carry out a comprehensive impact evaluation of vapor products.
“Science is the foundation of trust. As the industry leader, we have the responsibility to expand the borders of e-cigarette science and explore the unknown,” said Kate Wang, founder and CEO of RELX.
At the RELX Lab Open Day, RELX also announced its plan to establish a “1+4” scientific research approach—i.e. anchored by Platform Development, followed by Toxicological Assessment, Clinical Assessment, Perception Behavior Study and Long Term Assessment.
According to Public Health England, e-cigarettes are 95% less harmful to health than smoking and have the potential to help smokers quit smoking. Many consumers have recognized e-cigarettes as a better alternative to traditional combustible cigarettes.
There are still many areas that require further long-term research, such as the actual harm reduction elements of e-cigarettes, the maximization of their harm reduction, and other potential effects of vaping.
“E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge,” said Yilong Wen, RELX Co-founder and Head of Science, Research and Development and Supply Chain, “The RELX bioscience lab’s mission is to explore the unknown. We want to collect evidence through a scientific approach and strive to prove the potential for e-cigarettes to be less harmful, and in doing so, provide users the option to choose an alternative.
To ensure the reliability and quality of RELX products, RELX established a chemical and physical laboratory in 2018. The laboratory is certified by the internationally recognized China National Accreditation Service for Conformity Assessment. RELX started its groundbreaking research on the toxicological and pharmacological study on its products in 2019, and the new bioscience lab will focus on vivo and in vitro tests, as well as conduct pre-clinical safety assessments in 2020.
“The toxicological and pharmacological studies focus on the effects of RELX’s products,” said Xingtao Jiang, Head of RELX Lab, “For example, does it affect DNA or chromosomes, and what are the ingredients’ long-term impact on body organs and tissues? There is still a lot of research to be done.”
Xingtao Jiang also announced five preliminary findings from RELX’s research so far. Among these were that according to the data, the levels of harmful substances such as benzene and four TSNAs (Tobacco-specific N-nitrosoamines) emitted by RELX products are lower than those found in combustible cigarette smoke by over 99.1 percent and 99.8 percent respectively.
RELX is currently conducting research projects on different topics with six universities including the Sun Yat-sen University and Shenzhen Institutes of Advanced Technology, the Chinese Academy of Sciences, two hospitals and nine scientific research institutions.
ABOUT RELX Technology
Founded in January 2018, RELX is Asia’s leading e-cigarette brand. RELX independently develops its e-cigarette products at its R&D center in Shenzhen, China. RELX’s mission is to empower adult smokers through technology, product and science, ethically. RELX continues to make significant investments in R&D, e-liquid testing and new product development. The company has attracted global talents from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. RELX investors include top venture capital firms Source Code Capital, IDG Capital, and Sequoia Capital.
Website: https://relxnow.com
Twitter: @Relxtech
Facebook: @Relxnow
Instagram: relxtech
Linkedin: RELX Technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005346/en/
Contact information
Yasha Wolfman
yasha.wolfman@relxtech.com
Aimee Ren
aimee.ren@relxtech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom